Table 1 Summary of the studies on HLA-B27 antigen prevalence in SpA and the normal population in Middle Eastern and Arab Countries

Algeria

129 AS (ESSG and NY)

76 healthy blood donors

4%

69%

54.14 [16.09–182.18]

[17]

Egypt

380 normal individuals

4.7%

[18]

Egypt

75 SpA (ESSG) including 34 AS

58.7%

[19]

Egypt

100 healthy controls

1%

[20]

Iraq

25 AS

2.1%

84%

[21]

Iran

60 AS

430 healthy blood donors

3.95%

66.67%

48.59 [23.57–100.17]

[22]

Iran

119 AS

68.91%

[23]

Iran

98 AS (NY)

73.4%

[24]

Israel

38 AS

456 normal individuals

3%

79%

[25]

Jordan

22 AS (NY)

75%

[26]

Jordan / Qatar

129 AS

2579 healthy individuals

2.4%

72.22%

104.87 [66.21–166.11]

[12]

Kuwait

58 SpA (27 AS)

69.43%

82.56%

[27]

Kuwait

35 SpA + AS patients

544 controls

4%

25.7%

8.21 [3.44–19.60]

[28]

Lebanon

105 SpA (ESSG)

24 AS (NY)

841 Rheumatolgy patients

1.44%

13.85%

26.32%

24.46 [7.78–68.19]

[29]

Morocco

46 AS + coxitis

183 healthy controls

6.16%

58.70%

22.09 [9.48–51.49]

[30]

Morocco

49 SpA (Amor and ESSG)

67%

[31]

Oman

321 healthy

0.3%

[32]

Qatar

119 AS (NY)

74%

[33]

Saudi Arabia

12 AS

66.67%

[34]

Syria

50 AS (NY)

217 healthy controls

1.4%

60%

105.64 [29.98–381.87]

[35]

Tunisia

365 AS and/or BD

124 controls

3.2%

42.9%

[36]

Tunisia

100 AS (NY)

100 healthy controls

3%

62%

52.75 [15.61–178.31]

[37]

Tunisia

50 AS (Amor / ESSG)

69%

[38]

Turkey

112 AS (NY)

55 controls

2.8–6.8%

70%

29.82 [9.99–89.05]

[39]

Turkey

216 AS (67 analyzed)

91%

[40]

UAE

760 healthy

6.4%

[41]

UAE

17 AS

56%

[42]